Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Illumina (NASDAQ:ILMN) issued its earnings results on Thursday. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.13, FiscalAI reports. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. Illumina updated its FY 2026 guidance to 5.050-5.200 EPS.

Illumina Trading Down 0.4%

Illumina stock traded down $0.58 during trading hours on Thursday, reaching $133.61. The company had a trading volume of 2,936,281 shares, compared to its average volume of 2,130,796. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. Illumina has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a 50-day moving average price of $138.59 and a 200 day moving average price of $115.87. The firm has a market cap of $20.42 billion, a price-to-earnings ratio of 29.96, a P/E/G ratio of 2.25 and a beta of 1.45.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of Illumina during the 3rd quarter worth approximately $32,000. Advisory Services Network LLC purchased a new position in shares of Illumina in the 3rd quarter valued at approximately $102,000. Headlands Technologies LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $165,000. Voleon Capital Management LP purchased a new stake in Illumina in the third quarter worth $220,000. Finally, Glenmede Investment Management LP purchased a new stake in Illumina in the third quarter worth $220,000. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

ILMN has been the topic of several analyst reports. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday, October 31st. Barclays boosted their price objective on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Finally, UBS Group boosted their price target on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $127.18.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.